ELECSYS ANTI-HCV IMMUNOASSAY & ELECSYS PRECICONTROL ANTI-HCV FOR USE ON MODULAR ANALYTICS E170 IMMUNOSSAY ANALYZER

Assay, Enzyme Linked Immunosorbent, Hepatitis C Virus

FDA Premarket Approval P090009

This medical device has supplements. The device description/function or indication may have changed. Be sure to look at the supplements to get an up-to-date information on device changes. The labeling included below is the version at time of approval of the original pma or panel track supplement and may not represent the most recent labeling.

Pre-market Approval Supplement Details

Approval for the elecsysanti-hcv immunoassay & elecsys precicontrol anti-hcv assay for use on modular analytics e170 analyzer. This device is indicated for:elecsys anti-hcv immunoassaythe roche elecsys anti-hcv assay is an in vitro diagnostic test for the qualitativedetection of total antibodies to hepatitis c virus (anti-hcv) in human serum or plasma (potassium edta, lithium heparin and sodium heparin). Assay results, in conjunction withother laboratory results and clinical information, may be used to aid in the presumptive diagnosis of hcv infection in persons with signs and symptoms of hepatitis and in persons at risk for hepatitis c infection. The test does not determine the state of infection or associated disease. The electrochemilumi-nescence immunoassay "eclia" is intended for use on the modular analytics e170 immunoassay analyzer.

DeviceELECSYS ANTI-HCV IMMUNOASSAY & ELECSYS PRECICONTROL ANTI-HCV FOR USE ON MODULAR ANALYTICS E170 IMMUNOSSAY ANALYZER
Classification NameAssay, Enzyme Linked Immunosorbent, Hepatitis C Virus
Generic NameAssay, Enzyme Linked Immunosorbent, Hepatitis C Virus
ApplicantROCHE DIAGNOSTICS CORP.
Date Received2009-05-15
Decision Date2010-04-29
Notice Date2010-06-14
PMAP090009
SupplementS
Product CodeMZO
Docket Number10M-0264
Advisory CommitteeMicrobiology
Expedited ReviewNo
Combination Product No
Applicant Address ROCHE DIAGNOSTICS CORP. 9115 Hague Rd. indianapolis, IN 46250
Summary:Summary of Safety and Effectiveness
Labeling: Labeling
Approval Order: Approval Order

Supplemental Filings

Supplement NumberDateSupplement Type
P090009Original Filing
S018 2018-10-26 Normal 180 Day Track No User Fee
S017 2017-10-11 Real-time Process
S016 2017-08-03 30-day Notice
S015 2016-02-16 30-day Notice
S014 2016-01-27 30-day Notice
S013 2015-10-07 30-day Notice
S012 2014-08-22 30-day Notice
S011 2012-11-30 30-day Notice
S010 2012-09-05 30-day Notice
S009
S008 2012-02-29 30-day Notice
S007 2012-01-31 135 Review Track For 30-day Notice
S006 2011-11-21 30-day Notice
S005 2011-08-29 135 Review Track For 30-day Notice
S004 2011-08-17 135 Review Track For 30-day Notice
S003 2011-05-17 Normal 180 Day Track No User Fee
S002 2011-04-11 30-day Notice
S001 2010-07-28 Normal 180 Day Track

© 2024 FDA.report
This site is not affiliated with or endorsed by the FDA.